imatinib has been researched along with s 1033 in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.00) | 29.6817 |
| 2010's | 22 (73.33) | 24.3611 |
| 2020's | 5 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, KL; Bürckstümmer, T; Colinge, J; Ellmeier, W; Hantschel, O; Kneidinger, M; Rix, U; Schmidt, U; Schütze, G; Superti-Furga, G; Valent, P | 1 |
| Hilvo, M; Innocenti, A; Kallio, H; Parkkila, S; Scozzafava, A; Supuran, CT | 1 |
| Azam, M; Banda, G; Broudy, MI; Clackson, T; Daley, GQ; Dalgarno, DC; Das, S; Huang, WS; Iuliucci, J; Keats, J; Lentini, SP; Liu, S; Ning, Y; Russian, K; Sawyer, TK; Shakespeare, WC; Snodgrass, JT; Sundaramoorthi, R; Thomas, RM; Wang, F; Wang, Y; Wardwell, S; Wen, D; Xu, Q; Zhu, X | 1 |
| Morphy, R | 1 |
| Cowan-Jacob, SW; Gallagher, N; Kaufman, S; Manley, PW; Mestan, J; Stiefl, N; Wartmann, M; Wiesmann, M; Woodman, R | 1 |
| Cai, Q; Ding, K; Feng, Y; Gan, J; Li, X; Lu, X; Luo, K; Ren, X; Tu, Z; Wan, J; Wang, D; Yingxue, L; Zhang, F; Zhang, Z | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Ding, K; Leng, F; Li, Y; Long, H; Lu, X; Luo, J; Pan, X; Ren, X; Shen, M; Tu, Z; Wen, D; Zhang, F; Zhang, Z | 1 |
| Bai, Y; Ding, K; Feng, Y; Lang, X; Leng, F; Li, Y; Liu, J; Long, H; Lu, X; Luo, J; Pan, J; Pan, X; Ren, X; She, M; Tu, Z; Wang, D; Wen, D; Zhang, F; Zhang, Z; Zhuang, X | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bullock, AN; Canning, P; Choi, HG; Ezell, SA; Gray, NS; Griffin, JD; Kim, HG; Lee, SW; Liu, F; Liu, Q; Mandinova, A; Tan, L; Wang, J; Weisberg, EL; Wu, H; Zhao, Z | 1 |
| Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
| Ding, K; Li, Y; Lu, X; Ren, X | 1 |
| Ding, K; Lu, X; Luo, J; Pan, X; Ren, X; Wang, D; Yu, R; Zhang, Z; Zhuang, X | 1 |
| Chen, C; Hu, Z; Liang, X; Liu, J; Liu, Q; Liu, X; Lv, F; Qi, S; Qi, Z; Wang, A; Wang, B; Wang, L; Wang, W; Zhang, S; Zhao, Z; Zou, F | 1 |
| Bai, C; Chen, Y; Ding, K; Ding, Y; Geng, Y; Li, LY; Liu, JW; Sang, F; Sun, B; Sun, J; Wang, J; Wu, LL; Yang, G; Zhang, Q; Zhang, Z | 1 |
| Beleh, OM; Brandvold, KR; Johnson, TK; Kwarcinski, FE; Meagher, JL; Phadke, S; Seeliger, MA; Soellner, MB; Stuckey, JA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Addová, G; Boháč, A; Dobiaš, J; Hanquet, G; Murár, M; Šramel, P | 1 |
| Chong, FS; Eschweiler, JD; Hwang, SY; Majmudar, JD; Martin, BR; Ruotolo, BT; Won, SJ | 1 |
| Munoz, L | 1 |
| Jahnke, W; Skora, L | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Berellini, G; Buonamici, S; Cotesta, S; Cowan-Jacob, SW; Dodd, S; Drueckes, P; Fabbro, D; Furet, P; Gabriel, T; Groell, JM; Grotzfeld, RM; Hassan, AQ; Henry, C; Iyer, V; Jahnke, W; Jones, D; Lombardo, F; Loo, A; Manley, PW; Marzinzik, AL; Pellé, X; Rummel, G; Salem, B; Schoepfer, J; Warmuth, M; Wylie, AA; Zoller, T | 1 |
| Jia, W; Wang, X; Xi, Q; Yang, M | 1 |
| Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Hao, RR; Huang, WH; Liang, MH; Pan, YL; Shen, ZR; Zeng, SX | 1 |
| Bruyneel, AAN; Hnatiuk, AP; Malhotra, SV; Mercola, M; Pandrala, M | 1 |
| Allan, JM; Blair, HJ; Dannoura, A; Dueñas, ME; Heidenreich, O; Heunis, T; Inns, J; Marín-Rubio, JL; Martin, MP; Peltier-Heap, RE; Saxty, B; Scott, J; Simpson, AJ; Trost, M; Watt, JE | 1 |
7 review(s) available for imatinib and s 1033
| Article | Year |
|---|---|
Selectively nonselective kinase inhibition: striking the right balance.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Humans; Protein Binding; Protein Kinase Inhibitors; Structure-Activity Relationship | 2010 |
Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.
Topics: Amino Acid Sequence; Animals; Discoidin Domain Receptors; Drug Discovery; Humans; Inflammation; Ligands; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Small Molecule Libraries | 2015 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Non-kinase targets of protein kinase inhibitors.
Topics: Animals; Drug Design; Drug Evaluation, Preclinical; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Kinases | 2017 |
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
23 other study(ies) available for imatinib and s 1033
| Article | Year |
|---|---|
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Topics: Animals; Basophils; Dasatinib; Enzyme-Linked Immunosorbent Assay; Fusion Proteins, bcr-abl; Histamine Release; Humans; K562 Cells; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; U937 Cells | 2007 |
The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.
Topics: Animals; Benzamides; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Catalysis; Chemistry, Pharmaceutical; Drug Design; Humans; Hydrogen-Ion Concentration; Imatinib Mesylate; Kinetics; Models, Chemical; Molecular Conformation; Piperazines; Protein Isoforms; Protein-Tyrosine Kinases; Pyrimidines; Zinc | 2009 |
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Topics: Animals; Drug Design; Female; Humans; K562 Cells; Mice; NIH 3T3 Cells; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Purines; Rats; src-Family Kinases; Structure-Activity Relationship | 2009 |
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.
Topics: Benzamides; Cell Line; Cell Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship | 2010 |
Hybrid compounds as new Bcr/Abl inhibitors.
Topics: Cell Line, Tumor; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Leukemia; Models, Molecular; Structure-Activity Relationship; Thiazoles | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Threonine | 2012 |
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Spectrometry, Mass, Electrospray Ionization | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.
Topics: Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Discoidin Domain Receptor 1; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2013 |
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |
Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.
Topics: Cell Proliferation; Fusion Proteins, bcr-abl; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Pyrimidines | 2015 |
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Le
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; src-Family Kinases; Structure-Activity Relationship | 2016 |
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Molecular Structure; Peptides, Cyclic; Structure-Activity Relationship | 2016 |
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Topics: Animals; Chickens; Dasatinib; Drug Design; Humans; Molecular Docking Simulation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases | 2016 |
Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Topics: Alternative Splicing; Amines; Binding Sites; Drug Discovery; Humans; Ligands; Oxazoles; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Affinity-Based Selectivity Profiling of an In-Class Selective Competitive Inhibitor of Acyl Protein Thioesterase 2.
Topics: | 2017 |
Topics: | 2017 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
Topics: Allosteric Regulation; Animals; Dogs; Drug Discovery; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Models, Molecular; Molecular Structure; Mutation; Niacinamide; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Protein Kinase Inhibitors | 2019 |
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors | 2022 |
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proteome; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2022 |